Mutational analysis of ribosomal proteins in a cohort of pediatric patients with T-cell acute lymphoblastic leukemia reveals Q123R, a novel mutation in RPL10.
Q123R
RPL10 mutation
leukemia
next generation sequencing—NGS
ribosome
translation
uL16 (RPL10)
Journal
Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
09
2022
accepted:
07
11
2022
entrez:
9
12
2022
pubmed:
10
12
2022
medline:
10
12
2022
Statut:
epublish
Résumé
T-cell acute lymphoblastic leukemia (T-ALL) is a subtype of ALL involving the malignant expansion of T-cell progenitors. It is driven by a number of different possible genetic lesions, including mutations in genes encoding for ribosomal proteins (RPs). These are structural constituents of ribosomes, ubiquitous effectors of protein synthesis. Albeit the R98S mutation in RPL10, recurring with a higher frequency among RP mutations, has been extensively studied, less is known about the contribution of mutations occurring in other RPs. Alterations affecting translational machinery may not be well tolerated by cells, and there may be a selective pressure that determines the emergence of mutations with a compensatory effect. To explore this hypothesis, we sequenced the exomes of a cohort of 37 pediatric patients affected by T-ALL, and analyzed them to explore the co-occurrence of mutations in genes involved in ribosome biogenesis (including RPs) and translational control, and in known T-ALL driver genes. We found that some of the mutations in these sub-classes of genes tend to cluster together in different patients, indicating that their co-occurrence may confer some kind of advantage to leukemia cells. In addition, our sequencing highlighted the presence of a novel mutation in RPL10, namely the Q123R, which we found associated with a defect in protein synthesis. Our findings indicate that genetic alterations involving ribosome biogenesis and translational control should be carefully considered in the context of precision medicine in T-ALL.
Identifiants
pubmed: 36482893
doi: 10.3389/fgene.2022.1058468
pii: 1058468
pmc: PMC9723238
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1058468Informations de copyright
Copyright © 2022 Bacci, Indio, Rambaldelli, Bugarin, Magliocchetti, Del Rio, Pollutri, Melchionda, Pession, Lanciotti, Dufour, Gaipa, Montanaro and Penzo.
Déclaration de conflit d'intérêts
ADR is managing director of Innovamol Consulting Srl. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Science. 2011 Dec 16;334(6062):1524-9
pubmed: 22096102
J Pediatr Hematol Oncol. 2013 May;35(4):245-52
pubmed: 23612374
Cells. 2019 Jan 15;8(1):
pubmed: 30650663
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Nat Commun. 2019 Jun 11;10(1):2542
pubmed: 31186416
Blood. 2012 Nov 1;120(18):3764-73
pubmed: 22976955
Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5640-5
pubmed: 24706786
Cancer Discov. 2021 May;11(5):1082-1099
pubmed: 33408242
Nat Genet. 2022 Sep;54(9):1376-1389
pubmed: 36050548
Nature. 2012 Jan 11;481(7380):157-63
pubmed: 22237106
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Mol Psychiatry. 2006 Dec;11(12):1073-84
pubmed: 16940977
Leukemia. 2018 Mar;32(3):809-819
pubmed: 28744013
Nucleic Acids Res. 2020 Feb 20;48(3):1013-1028
pubmed: 31350888
Blood. 2017 Mar 2;129(9):1113-1123
pubmed: 28115373
Leukemia. 2018 Jun;32(6):1358-1369
pubmed: 29740158
J Clin Invest. 2012 Oct;122(10):3398-406
pubmed: 23023710
Nat Genet. 2017 Aug;49(8):1211-1218
pubmed: 28671688
Oncogene. 2016 Sep 8;35(36):4675-88
pubmed: 26829052
Curr Opin Genet Dev. 2011 Aug;21(4):474-83
pubmed: 21543223
Genetics. 2014 Oct;198(2):723-33
pubmed: 25316788
EMBO J. 2022 Apr 19;41(8):e109823
pubmed: 35315941
Oncogene. 2015 Jul;34(27):3593-604
pubmed: 25241901
N Engl J Med. 2015 Oct 15;373(16):1541-52
pubmed: 26465987
Nat Genet. 2013 Feb;45(2):186-90
pubmed: 23263491
Oncotarget. 2017 Sep 11;8(52):89427-89428
pubmed: 29163758
J Clin Oncol. 2015 Sep 20;33(27):2938-48
pubmed: 26304874
Leukemia. 2019 Feb;33(2):319-332
pubmed: 29930300
Cancer Discov. 2014 Jan;4(1):61-8
pubmed: 24265154
Cancer Cell. 2016 Dec 12;30(6):849-862
pubmed: 27916615
Int J Mol Sci. 2021 Apr 26;22(9):
pubmed: 33925883
Int J Oncol. 2016 Apr;48(4):1313-24
pubmed: 26892688
Cytometry B Clin Cytom. 2020 Nov;98(6):491-503
pubmed: 32479694
Nat Methods. 2009 Apr;6(4):275-7
pubmed: 19305406
Cells. 2020 Nov 19;9(11):
pubmed: 33227977
Nat Med. 2013 Mar;19(3):368-71
pubmed: 23377281